I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Capricor (CAPR) bites the bullet that they fired at itself

May 12, 2017

Shares of CAPR closed down - $1.89 or -62% to $1.16 and is now laying-off employees following the failure of its mid-stage cardiovascular drug trial while the controversial CEO remains at the helm ...  

Kite Pharma (KITE) is falling due to the death of a cancer patient from brain swelling following treatment with its CAR-T therapy KTE-C19.

May 8, 2017

The death has distressed investors because death from brain swelling, or cerebral edema, is the same severe toxic event that scuttled a competing CAR-T therapy from Juno Therapeutics (JUNO).  

Randy Mills' Departs the California Institute for Regenerative Medicine (CIRM) in June

May 3, 2017

  Disappointment, shock and surprise are surfacing in the wake of the news that Randy Mills is leaving his post as CEO of the California stem cell agency.  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.